We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+2.04%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$681M
AUM Growth
-$84.8M
Cap. Flow
-$23.2M
Cap. Flow %
-3.41%
Top 10 Hldgs %
54.41%
Holding
74
New
15
Increased
15
Reduced
15
Closed
16

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$38.2M
2
AUTL
Autolus Therapeutics
AUTL
+$15.6M
3
IMVT icon
Immunovant
IMVT
+$12.3M
4
IRON icon
Disc Medicine
IRON
+$12.1M
5
KROS icon
Keros Therapeutics
KROS
+$9.98M

Top Sells

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$41.5M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$21.7M
3
TGTX icon
TG Therapeutics
TGTX
+$20.2M
4
CRDF icon
Cardiff Oncology
CRDF
+$13.2M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$9.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTX icon
26
Avalo Therapeutics
AVTX
$1.08B
$7.85M 1.15%
903
-7
-0.8% -$66.1K
STRO icon
27
Sutro Biopharma
STRO
$353M
$7.78M 1.14%
34,195
+1,975
+6% +$469K
PTGX icon
28
Protagonist Therapeutics
PTGX
$9.67B
$7.69M 1.13%
297,000
+37,000
+14% +$936K
IMVT icon
29
Immunovant
IMVT
$9.05B
$7.49M 1.1%
+467,000
New +$12.3M
PCVX icon
30
Vaxcyte
PCVX
$9.1B
$7.07M 1.04%
357,800
+22,600
+7% +$569K
SMTI icon
31
Sanara MedTech
SMTI
$318M
$7.01M 1.03%
+225,000
New +$7.8M
GYRE icon
32
Gyre Therapeutics
GYRE
$708M
$6.3M 0.93%
166,667
+146,827
+740% +$6.71M
AVEO
33
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$6.11M 0.9%
835,000
+776,200
+1,320% +$6.7M
KNSA icon
34
Kiniksa Pharmaceuticals
KNSA
$6.23B
$5.94M 0.87%
320,926
+96,826
+43% +$1.98M
VSTM icon
35
Verastem
VSTM
$668M
$5.74M 0.84%
193,750
– –
TELA icon
36
TELA Bio
TELA
$29.2M
$5.44M 0.8%
365,000
– –
LITS
37
Lite Strategy Inc
LITS
$34M
$5.34M 0.78%
77,800
– –
CRDF icon
38
Cardiff Oncology
CRDF
$76.7M
$5.33M 0.78%
576,000
-1,086,500
-65% -$13.2M
SIOX
39
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.22M 0.77%
2,000,000
– –
APTO
40
DELISTED
Aptose Biosciences, Inc.
APTO
$5.21M 0.77%
1,937
+159
+9% +$315K
MYOV
41
DELISTED
Myovant Sciences Ltd.
MYOV
$5.14M 0.76%
249,800
-432,700
-63% -$9.85M
KYNB
42
Kyntra Bio
KYNB
$32.4M
$5.1M 0.75%
5,880
– –
LUMO
43
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.41M 0.65%
376,900
+95,613
+34% +$1.61M
KZR
44
DELISTED
Kezar Life Sciences
KZR
$4.24M 0.62%
71,120
+320
+0.5% +$18.7K
OPTN
45
DELISTED
OptiNose
OPTN
$3.05M 0.45%
55,067
+26,067
+90% +$1.59M
QSI icon
46
Quantum-Si Incorporated
QSI
$176M
$2.88M 0.42%
+241,300
New +$2.92M
CRNX icon
47
Crinetics Pharmaceuticals
CRNX
$9B
$2.87M 0.42%
+188,000
New +$2.91M
FOCL
48
EDAP TMS S.A.
FOCL
$199M
$2.87M 0.42%
341,300
-316,200
-48% -$2.57M
SRRA
49
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.6M 0.38%
151,139
+75,760
+101% +$1.2M
BHVN
50
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.71M 0.25%
25,000
-89,000
-78% -$7.2M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2021 Portfolio in Review

As of Q1 2021, Opaleye Management held 74 positions worth $681M, down 11% from $766M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Opaleye Management withdrew a net $23.2M in Q1 2021, closing 16 positions and reducing 15 holdings. Its most notable exit was Eidos Therapeutics, Inc. Common Stock, an estimated $41.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Opaleye Management opened a new position in BridgeBio Pharma worth $36M.

  • Opaleye Management's largest Q1 2021 buy was BridgeBio Pharma: 583,767 shares worth $36M.
  • Opaleye Management added most to MacroGenics in Q1 2021, an estimated $7.18M increase.
  • Opaleye Management's biggest Q1 2021 reduction was Cardiff Oncology, cutting an estimated $13.2M.
  • Opaleye Management fully exited Eidos Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $41.5M.
  • Opaleye Management's ten largest holdings make up 54% of its $681M portfolio in Q1 2021.
  • Opaleye Management opened 15 new positions and closed 16 in Q1 2021.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $681M.

Based on Opaleye Management's 13F filing for Q1 2021, filed 18 May 2021.